UCB SA (UCB) - Financial and Strategic SWOT Analysis Review
June 2019
59
About the Report
About the Report
UCB SA (UCB)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description-A detailed description of the company's operations and business divisions.
- Corporate strategy-Analyst's summarization of the company's business strategy.
- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history-Progression of key events associated with the company.
- Major products and services-A list of major products, services and brands of the company.
- Key competitors-A list of key competitors to the company.
- Key employees-A list of the key executives of the company.
- Executive biographies-A brief summary of the executives' employment history.
- Key operational heads-A list of personnel heading key departments/functions.
- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities-A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylorthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. The company operates through subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.
UCB SA Key Recent Developments
Jun 04,2019: UCB Boston research is advancing medical innovation
Mar 12,2019: Ireland to lead EUR7 million Parkinson's research project
Feb 28,2019: UCB full year report 2018: 2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB's strong pipeline
Feb 12,2019: UCB and Epilepsy Society partner to bring targeted treatments
Jan 18,2019: New online resource from AGA and the IBD parenthood project, in collaboration with multidisciplinary experts, provides guidance and dispels fears about pregnancy for women with IBD
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Products
Products
UCB SA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Companies
Servier Laboratories Ltd
Novartis AG
Merck Serono SA
Johnson & Johnson
GlaxoSmithKline Plc
Eli Lilly and Co
Biotie Therapies Corp
Bausch Health Companies Inc
AstraZeneca Plc
Amgen Inc
Table of Contents
Table of Contents
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1-About the Company
UCB SA-Key Facts
UCB SA-Key Employees
UCB SA-Key Employee Biographies
UCB SA-Major Products and Services
UCB SA-History
UCB SA-Company Statement
UCB SA-Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2-Company Analysis
Company Overview
UCB SA-Business Description
Product Category: Established Brands
Overview
Performance
Product Category: Immunology
Overview
Performance
Product Category: Neurology
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: International Markets
Performance
Geographical Segment: US
Performance
R&D Overview
UCB SA-Corporate Strategy
UCB SA-SWOT Analysis
SWOT Analysis-Overview
UCB SA-Strengths
UCB SA-Weaknesses
UCB SA-Opportunities
UCB SA-Threats
UCB SA-Key Competitors
Section 3-Company Financial Ratios
Financial Ratios-Capital Market Ratios
Financial Ratios-Annual Ratios
Performance Chart
Financial Performance
Financial Ratios-Interim Ratios
Financial Ratios-Ratio Charts
Section 4-Company's Lifesciences Financial Deals and Alliances
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
UCB SA, Recent Deals Summary
Section 5-Company's Recent Developments
Jun 04, 2019: UCB Boston research is advancing medical innovation
Mar 12, 2019: Ireland to lead EUR7 million Parkinson's research project
Feb 28, 2019: UCB full year report 2018: 2018 marks the fifth consecutive year of profitable growth, intensifying investment in UCB's strong pipeline
Feb 12, 2019: UCB and Epilepsy Society partner to bring targeted treatments
Jan 18, 2019: New online resource from AGA and the IBD parenthood project, in collaboration with multidisciplinary experts, provides guidance and dispels fears about pregnancy for women with IBD
Dec 05, 2018: UCB to invest in UK healthcare innovations
Oct 30, 2018: UCB first nine months interim report 2018: UCB tracking well towards full year financial outlook
Oct 24, 2018: UCB brings HR to the cloud with SAP successFactors solutions
Oct 05, 2018: New online patent-search tool launched
Sep 05, 2018: New approach accelerates drug discovery
Section 6-Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Figure
List of Figures
UCB SA, Performance Chart (2014-2018)
UCB SA, Ratio Charts
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
List of Table
List of Tables
UCB SA, Key Facts
UCB SA, Key Employees
UCB SA, Key Employee Biographies
UCB SA, Major Products and Services
UCB SA, History
UCB SA, Subsidiaries
UCB SA, Joint Venture
UCB SA, Key Competitors
UCB SA, Ratios based on current share price
UCB SA, Annual Ratios
UCB SA, Annual Ratios (Cont...1)
UCB SA, Annual Ratios (Cont...2)
UCB SA, Interim Ratios
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
UCB SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.